多发性骨髓瘤随机试验的网络Meta分析:复发/难治患者的疗效与安全性
该研究对复发/难治多发性骨髓瘤(RRMM)方案进行系统评价、两项标准配对Meta分析和网络Meta分析(NMA),配对Meta分析纳入16项试验、NMA纳入18项试验。配对Meta分析显示含硼替佐米或免疫调节酰亚胺药物(IMiD)的三药方案在无进展生存期(PFS)和总缓解率(ORR)上优于两药方案;NMA显示以IMiD为骨架联合抗MM单克隆抗体(mAb)(优先)或蛋白酶体抑制剂的方案成为最有效且毒性最低方案的概率最高。
要点
- 配对Meta分析中,含硼替佐米或IMiD的三药方案在PFS和ORR上优于两药方案。
- NMA中,IMiD联合抗MM单克隆抗体(优先)或蛋白酶体抑制剂的方案成为最有效且毒性最低方案的概率最高。
- 达雷妥尤单抗+来那度胺+地塞米松在PFS、OS、ORR、完全缓解率和安全性的累积排名曲线下面积平均值上排名第一。
核心结论
- 作者认为,IMiD联合含新型抗MM单克隆抗体的方案是RRMM中最具活性的治疗选择。
- 该分析是首个比较已发表随机试验中所有当前可用RRMM方案的NMA,但结果需结合患者人群差异解读。
研究设计与样本
- 系统评价、两项标准配对Meta分析和一项网络Meta分析(NMA)。
- 配对Meta分析纳入16项试验,NMA纳入18项试验。
- 配对Meta分析评估与硼替佐米或免疫调节酰亚胺药物(IMiD)直接头对头比较的方案疗效。
- NMA基于所有可用的直接和间接证据确定各方案的相关性。
主要发现
- 配对Meta分析显示,含硼替佐米或IMiD的三药方案在PFS和ORR上优于两药方案。
- NMA显示,以IMiD为骨架联合抗MM单克隆抗体(优先)或蛋白酶体抑制剂的方案成为最有效且毒性最低方案的概率最高。
- 达雷妥尤单抗、来那度胺和地塞米松联合方案在PFS、OS、ORR、完全缓解率和安全性的累积排名曲线下面积平均值上排名第一。
局限性
- 作者指出,结果需结合所纳入试验患者人群的差异来解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite major therapeutic advancements, multiple myeloma (MM) is still incurable and relapsed/refractory multiple myeloma (RRMM) remains a challenge; the rational choice of the most appropriate regimen in this setting is currently undefined. We performed a systematic review and 2 standard pairwise meta-analyses to evaluate the efficacy of regimens that have been directly compared with bortezomib or immunomodulatory imide drugs (IMiDs) in head-to-head clinical trials and a network meta-analysis (NMA) to determine the relevance of each regimen on the basis of all the available direct and indirect evidence. Sixteen trials were included in the pairwise meta-analyses, and 18 trials were included in the NMA. Pairwise meta-analyses showed that a 3-drug regimen (bortezomib- or IMiD-based) was superior to a 2-drug regimen in progression-free-survival (PFS) and overall response rate (ORR). NMA showed that an IMiD backbone associated with anti-MM monoclonal antibodies (mAbs) (preferably) or proteasome inhibitors had the highest probability of being the most effective regimen with the lowest toxicity. The combination of daratumumab, lenalidomide, and dexamethasone ranked as the first regimen in terms of activity, efficacy, and tolerability according to the average value between surface under the cumulative ranking curve of PFS, overall survival, ORR, complete response rate, and safety. This is the first NMA comparing all currently available regimens evaluated in published randomized trials for the treatment of RRMM, but our results need to be interpreted taking into account differences in their patient populations. Our analysis suggests that IMiDs plus new anti-MM mAb-containing regimens are the most active therapeutic option in RRMM.
引用
- Botta C, Ciliberto D, Rossi M, et al. Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. Blood Adv. 2017. PMID: 29296961. doi:10.1182/bloodadvances.2016003905
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。